Literature DB >> 25663677

B10 cells: a functionally defined regulatory B cell subset.

Thomas F Tedder1.   

Abstract

B cells are commonly thought to enhance inflammatory immune responses. However, specific regulatory B cell subsets recently were identified that downregulate adaptive and innate immunity, inflammation, and autoimmunity through diverse molecular mechanisms. In both mice and humans, a rare, but specific, subset of regulatory B cells is functionally characterized by its capacity to produce IL-10, a potent inhibitory cytokine. For clarity, this regulatory B cell subset has been labeled as B10 cells, because their ability to downregulate immune responses and inflammatory disease is fully attributable to IL-10, and their absence or loss exacerbates disease symptoms in mouse models. This review preferentially focuses on what is known about mouse B10 cell development, phenotype, and effector function, as well as on mechanistic studies that demonstrated their functional importance during inflammation, autoimmune disease, and immune responses.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663677     DOI: 10.4049/jimmunol.1401329

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  116 in total

1.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  The role of B-1 cells in inflammation.

Authors:  Monowar Aziz; Nichol E Holodick; Thomas L Rothstein; Ping Wang
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 3.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

5.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

6.  Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes.

Authors:  Jamie L Felton; Damian Maseda; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

Review 7.  Therapeutic Potential of B-1a Cells in COVID-19.

Authors:  Monowar Aziz; Max Brenner; Ping Wang
Journal:  Shock       Date:  2020-11       Impact factor: 3.454

8.  Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease.

Authors:  Anne-Christine Flach; Tanja Litke; Judith Strauss; Michael Haberl; César Cordero Gómez; Markus Reindl; Albert Saiz; Hans-Jörg Fehling; Jürgen Wienands; Francesca Odoardi; Fred Lühder; Alexander Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

9.  Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Authors:  Sara Lundqvist; Signe Modvig; Emilie A Fischer; Jette L Frederiksen; Matilda Degn
Journal:  Immunology       Date:  2018-12-27       Impact factor: 7.397

10.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.